share_log

B of A Securities Maintains Neutral on ProKidney, Raises Price Target to $4

B of A Securities Maintains Neutral on ProKidney, Raises Price Target to $4

Bof A证券对ProKidney维持中立,将目标股价上调至4美元
Benzinga ·  05/29 05:21

B of A Securities analyst Jason Gerberry maintains ProKidney (NASDAQ:PROK) with a Neutral and raises the price target from $3 to $4.

B of A Securities分析师杰森·格伯里维持ProKidney(纳斯达克股票代码:PROK)的中性评级,并将目标股价从3美元上调至4美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发